Tempus AI has announced that it is using the TIME Network for Phase I trials to expedite site activation and enrolment.

Among those consuming UPFs in high-income countries, intake varies significantly across age and socioeconomic status.

Immunic’s drug is currently being investigated in two Phase III trials in patients with relapsing multiple sclerosis.

The London Cancer Hub has been identified as a key district for ‘frontier innovation’ by London Mayor Sadiq Khan.